FindTrial
Sign In

Clinical study to investigate the effects of olmesartan and azelnidipine in patients with hypertesnion and arteriosclerosis obliterans

Clinical study to investigate the effects of olmesartan and azelnidipine in patients with hypertesnion and arteriosclerosis obliterans - Clinical study to investigate the effects of olmesartan and azelnidipine in patients with hypertesnion and arteriosclerosis obliterans

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000236
Enrollment
60
Registered
2008-01-01
Start date
2005-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with essential hypertension and arteriosclerosis obliterans(ASO)

Interventions

Olmesartan medoxomil will be administered during the study for one year. Azelnidipine will be administered during the study for one year.

Sponsors

Cardiovascular Hospital of Central Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients with ASO 2)ABPI(Ankle brachial pressure index) 140mmHg and sitting diastoric blood pressure > 90mmHg

Exclusion criteria

Exclusion criteria: 1) Fontane classification III or IV 2) Immediate requirement for surgical operation 3) Myocardial infarction, unstable angina pectoris, stroke or transient ischemic atttack within 6 months before giving informed consent 4) Deep-vein thrombosis within 3 months before giving informed consent 5) Malignancy that requires treatment 6) Liver dysfunction (AST and ALT>100IU/L) 7) Renal dysfunction (creatinine>3.0mg/dL)

Design outcomes

Primary

MeasureTime frame
Efficacy Changes from baseline in blood pressure (Casual blood pressure and ABPM) Changes from baseline in intima media thickness in femoral arteries and carotid arteries Safety Adverse event and laboratory tests—

Countries

Japan

Contacts

Public ContactHisao Kumakura

Cardiovascular Hospital of Central Japan Department of Internal Medicine

kumakura@sannet.ne.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026